![\"Agilent](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/06\/a2b9d2f7ab390a8d47ec13fccb14bcae.png\")
Agilent Total Revenue <\/p>\nAs the craze of earnings season draws to a close, here\u2019s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at research tools & consumables stocks, starting with Agilent (NYSE:A).<\/p>\n
The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives.<\/p>\n
The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts\u2019 consensus estimates by 1.3% while next quarter\u2019s revenue guidance was 2% above.<\/p>\n
Thankfully, share prices of the companies have been resilient as they are up 8.5% on average since the latest earnings results.<\/p>\n
Agilent (NYSE:A) <\/p>\n
Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets.<\/p>\n
Agilent reported revenues of $1.84 billion, up 10% year on year. This print exceeded analysts\u2019 expectations by 1.9%. Overall, it was a strong quarter for the company with an impressive beat of analysts\u2019 organic revenue estimates and a narrow beat of analysts\u2019 full-year EPS guidance estimates.<\/p>\n
Agilent Total Revenue <\/p>\n
Agilent scored the highest full-year guidance raise but had the weakest guidance update of the whole group. Unsurprisingly, the stock is up 7.6% since reporting and currently trades at $124.70.<\/p>\n
Is now the time to buy Agilent? Access our full analysis of the earnings results here, it\u2019s free<\/a>.<\/p>\n Best Q1: Waters Corporation (NYSE:WAT) <\/p>\n Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE:WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing.<\/p>\n Waters Corporation reported revenues of $1.27 billion, up 91.5% year on year, outperforming analysts\u2019 expectations by 4.5%. The business had a very strong quarter with a solid beat of analysts\u2019 organic revenue estimates and revenue guidance for next quarter exceeding analysts\u2019 expectations.<\/p>\n Waters Corporation delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. The market seems happy with the results as the stock is up 17.7% since reporting. It currently trades at $355.45.<\/p>\n Is now the time to buy Waters Corporation? Access our full analysis of the earnings results here, it\u2019s free<\/a>.<\/p>\n Slowest Q1: Revvity (NYSE:RVTY) <\/p>\n Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure.<\/p>\n Revvity reported revenues of $686.9 million, up 9.3% year on year, falling short of analysts\u2019 expectations by 2.6%. It was a softer quarter as it posted full-year revenue and EPS guidance estimates.<\/p>\n Revvity delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. Interestingly, the stock is up 15.6% since the results and currently trades at $99.98.<\/p>\n Read our full analysis of Revvity\u2019s results here. <\/a><\/p>\n Thermo Fisher (NYSE:TMO) <\/p>\n With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide.<\/p>\n Thermo Fisher reported revenues of $11.01 billion, up 6.2% year on year. This result topped analysts\u2019 expectations by 1.5%. Aside from that, it was a satisfactory quarter as it also logged a beat of analysts\u2019 EPS estimates but organic revenue in line with analysts\u2019 estimates.<\/p>\n The stock is down 10.1% since reporting and currently trades at $462.03.<\/p>\n Read our full, actionable report on Thermo Fisher here, it\u2019s free.<\/a><\/p>\n Bruker (NASDAQ:BRKR) <\/p>\n With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.<\/p>\n Bruker reported revenues of $823.4 million, up 2.7% year on year. This number surpassed analysts\u2019 expectations by 3.4%. It was a very strong quarter as it also put up a beat of analysts\u2019 EPS and organic revenue estimates.<\/p>\n The stock is up 52.6% since reporting and currently trades at $58.00.<\/p>\n Waters Corporation Total Revenue <\/p>\n